StockNews.com started coverage on shares of Organovo (NASDAQ:ONVO – Free Report) in a report released on Friday. The brokerage issued a sell rating on the medical research company’s stock.
Organovo Stock Performance
NASDAQ ONVO opened at $1.04 on Friday. The company has a market cap of $10.44 million, a PE ratio of -0.48 and a beta of 0.91. The firm’s 50 day moving average price is $1.04 and its 200-day moving average price is $1.12. Organovo has a 52-week low of $0.89 and a 52-week high of $2.05.
Organovo (NASDAQ:ONVO – Get Free Report) last posted its earnings results on Thursday, February 8th. The medical research company reported ($0.40) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.01. The company had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $0.08 million. On average, analysts forecast that Organovo will post -1.74 earnings per share for the current fiscal year.
Organovo Company Profile
Organovo Holdings, Inc, a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.
Featured Articles
- Five stocks we like better than Organovo
- 3 Warren Buffett Stocks to Buy Now
- The 3 Hottest Insiders Buys This Month
- How to Invest in the FAANG Stocks
- What Bulls and Bears May Be Getting Wrong about SOFI Stock
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- Microsoft Analysis: Trends, Predictions & Investment Insight
Receive News & Ratings for Organovo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organovo and related companies with MarketBeat.com's FREE daily email newsletter.
